



HANetf and Gins Global Extend Innovative Technology ETF Series with Global Healthcare Innovation UCITS ETF

HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) provides exposure to 88 Healthtech companies from Developed and Emerging Markets

Third ETF from Gins Global to launch via HANetf white-label platform

Listing on London Stock Exchange, Borsa Italiana and XETRA

London, April, 2018

HANetf, Europe's first independent 'white label' UCITS ETF issuer, is pleased to announce that the HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) will launch on London Stock Exchange, Borsa Italiana and XETRA in April, 2019 with a TER of 75bps.

EXCHANGE	BB CODE	RIC	ISIN	SEDOL	CCY	INCOME
London Stock Exchange	WELL	HAWELL.L	IE00BJQTJ848	BJVBGL7	USD	Acc
London Stock Exchange	WELP	WELP.L	IE00BJQTJ848	BJVBGM8	GBP	Acc
Borsa Italiana	WELL	WELL.MI	IE00BJQTJ848	BHRWXD1	EUR	Acc
XETRA	W311 GY	W311.DE	DE000A2PE7K4	BJ02354	EUR	Acc

WELL has been launched on HANetf's unique, independent white-label UCITS ETF platform with Gins Global Index Funds, as part of a series of thematic ETFs that provide exposure to innovative and emerging industrial and technological themes.

The new ETF tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index, enabling investors to gain exposure to companies at the forefront of healthcare innovation from both Developed and Emerging Markets. To be included, constituents must generate a majority of their revenues from innovative healthtech sectors including Bioinformatics, Bioengineering, Genome Sequencing, Healthcare Trackers, Nanotechnology, Neuroscience, Robotics and Medical Devices. The 88 current constituents have a combined market capitalisation of ~\$824 Billion.¹

Anthony Ginsberg, Founder and Managing Director, Gins Global Index Funds, said: *"Healthcare advances over the past 100 years have dramatically increased human lifespans and reduced the risk of death from communicable diseases like malaria or influenza. Technology and healthcare are now combining to create a faster, safer and more personalised generation of diagnostics, treatments and medicines. We are excited to offer WELL with HANetf, providing exposure to the companies at the forefront of these developments in a diversified, liquid and transparent format."*

¹ Source: Indxx. Data as of 12 March, 2019.



Hector McNeil, co-Founder and co-CEO, HANetf, said: *“We are pleased to introduce WELL, expanding our range of HAN-GINS ETFs which enable investors to incorporate long-term, transformational technological trends into their portfolios. Healthcare has been a core portfolio holding for decades, and with this new ETF, we go beyond ‘Big Pharma’ to capture the companies that are addressing the key healthcare and wellness challenges of our time. When it comes to healthcare, we hope all investors get WELL soon.”*

The launch of ‘WELL’ extends the HAN-GINS range of ETFs which target “Industry 4.0” themes. HAN-GINS Innovative Technologies UCITS ETF (ITEK) and HAN-GINS Cloud Technologies UCITS ETF (SKYY) were launched in October 2018.

Ends

Media Contacts:

Gregor Dickie, MRM Communications

Gregor.Dickie@MRM-London.com

+44 (0) 203 326 9918

Sara Vola, MyMediaRelation

Vola@MyMediaRelation.it

+39 02 36 75 15 11

About HANetf:

HANetf is an independent ETF specialist working with third-party asset managers to bring differentiated, modern and innovative ETF exposures to European investors.

Founded by two of Europe’s leading ETF entrepreneurs, Hector McNeil and Nik Bienkowski, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers who want to successfully launch and manage UCITS ETFs.

www.HANetf.com

About Gins Global:

Gins Global Index Funds is a global asset management company specializing in index mutual funds, structured products and capital guaranteed funds for institutional and private investors. Founded in 2000, the company manages over \$2 billion across its product suite and has operations in North America, Asia-Pacific, Middle East and Africa.

www.GinsGlobal.com

HAN-GINS Healthcare Innovation UCITS ETF						
EXCHANGE	BB CODE	RIC	ISIN	SEDOL	CCY	INCOME
London Stock Exchange	WELL LN	HAWELL.L	IE00BJQTJ848	BJVBGL7	USD	Acc
London Stock Exchange	WELP LN	WELP.L	IE00BJQTJ848	BJVBGM8	GBP	Acc
Borsa Italiana	WELL IM	WELL.MI	IE00BJQTJ848	BHRWXD1	EUR	Acc
XETRA	W311 GY	W311.DE	DE000A2PE7K4	BJ02354	EUR	Acc

HAN-GINS Cloud Technology UCITS ETF						
EXCHANGE	BB CODE	RIC	ISIN	SEDOL	CCY	INCOME
London Stock Exchange	SKYY LN	SKYY.L	IE00BDDRF924	BYVJ8T8	USD	Acc
London Stock Exchange	SKYP LN	SKYP.L	IE00BDDRF924	BYVJ9B7	GBP	Acc
Borsa Italiana	SKYY IM	SKYY.MI	IE00BDDRF924	BFX1CC0	EUR	Acc
XETRA	5XYE GY	5XYE.DE	DE000A2N5XC4	BFX38L7	EUR	Acc

HAN-GINS Innovative Technologies UCITS ETF						
EXCHANGE	BB CODE	RIC	ISIN	SEDOL	CCY	INCOME
London Stock Exchange	ITEK LN	ITEK.L	IE00BDDRF700	BYVJ8Y3	USD	Acc
London Stock Exchange	ITEP LN	ITEP.L	IE00BDDRF700	BYVJ9D9	GBP	Acc
Borsa Italiana	ITEK IM	ITEC.MI	IE00BDDRF700	BFX1C86	EUR	Acc
XETRA	T3KE GY	T3KE.DE	DE000A2N5XE0	BFX38M8	EUR	Acc

KMEFIC FTSE Kuwait Equity UCITS ETF						
EXCHANGE	BB CODE	RIC	ISIN	SEDOL	CCY	INCOME
London Stock Exchange	KUW8 LN	KUW8.L	IE00BGPBVS44	BGY9KV5	USD	Acc
London Stock Exchange	KUW8 LN	KUWP.L	IE00BGPBVS44	BGSXQZ9	GBP	Acc
Borsa Italiana	KUW8 IM	KUW8.MI	IE00BGPBVS44	BGSGKH8	EUR	Acc
XETRA	KUW8 GY	KUW8G.DE	IE00BGPBVS44	BJ9ZLG1	EUR	Acc

EMQQ Emerging Markets Internet & Ecommerce UCITS ETF						
EXCHANGE	BB CODE	RIC	ISIN	SEDOL	CCY	INCOME
London Stock Exchange	EMQQ LN	EMQQ.L	IE00BFYN8Y92	BYVJ906	USD	Acc
London Stock Exchange	EMQP LN	EMQP.L	IE00BFYN8Y92	BYVJ9P1	GBP	Acc
Borsa Italiana	EMQQ IM	EMQQ.MI	IE00BFYN8Y92	BFX1CD1	EUR	Acc
XETRA	EMQQ GY	EMQ1.DE	DE000A2N5XA8	BFX38K6	EUR	Acc

Important Information

The content in this document is issued by his document is issued by HANetf Limited ("HANetf"), an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority



("FCA"). For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included on this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided on this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements.

Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment. An investment in an ETF is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETFs involve numerous risks including among others, general market risks relating to the relevant underlying index, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the Issuers or their products are authorised or registered for distribution and where no prospectus of any of the Issuers has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the Issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes. The products discussed on this document are issued by HANetf ICAV.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements. HANetf ICAV is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with segregated liability between sub-funds and with variable capital organised under the laws of Ireland and authorised by the Central Bank of Ireland ("CBI"). Investors should read the prospectus of HANetf ICAV ("HANetf Prospectus") before investing and should refer to the section of the HANetf Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares